REG - Immupharma PLC - Grant of Options

ImmuPharmaAnnouncement

22/12/2022 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221222:nRSV6023Ka&default-theme=true

RNS Number : 6023K  Immupharma PLC  22 December 2022

 
22 December 2022

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

                      Grant of Share Options

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces the grant of share options as follows.

 

The Remuneration Committee (comprising the Non Executive Directors) has
determined to award  Share Options to the Executive Directors with exercise
prices and conditions which reflect the underlying objective of restoring and
enhancing shareholder value as follows:

 

Tim McCarthy                    1,800,000 share options
(exercise price £0.05)

Tim McCarthy                    1,800,000 share options
(exercise price £0.11)

Tim Franklin                       1,575,000 share options
(exercise price £0.05)

Tim Franklin                       1,575,000 share options
(exercice price £0.11)

 

Vesting & Performance conditions:

 

·    3 year vesting period; and

·    1st patient dosed in the next P140 (Lupuzor™) clinical trial.

 

ENDS

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis suggest
therapeutic activity for many other autoimmune diseases that share the same
autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim McCarthy
 2    Reason for the notification
 a)   Position/status                                              Chairman and Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Grant of share options over new Ordinary Shares
 c)   Price(s) and volume(s)                                       Exercise Price               Volume

      5 pence                                                                                   1,800,000
                                                                   11 pence                     1,800,000
 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      22 December 2022
 f)   Place of the transaction                                     n/a

 

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim Franklin
 2    Reason for the notification
 a)   Position/status                                              Chief Operating Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Grant of share options over new Ordinary Shares
 c)   Price(s) and volume(s)                                       Exercise Price               Volume

      5 pence                                                                                   1,575,000
                                                                   11 pence                     1,575,000
 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      22 December 2022
 f)   Place of the transaction                                     n/a

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUUOBRUBUUURA